Optimism amongst analysts is growing over Roche’s growth prospects and its ability to overcome looming threats from biosimilars and possible US pricing reforms, a trend that should be reinforced when the Swiss pharma presents a pipeline update in London on 16 September.
Roche’s Pipeline Prospects Promise Steady Sailing To More Growth
Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.
More from Strategy
More from Business
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.